In this review:
DVT: a US cost model
LMWH prophylaxis and mortality in acutely ill medical patients
Aspirin vs. dalteparin for VTE prevention after THA
Follow-up of the ‘Men Continue and Herdoo2’ cohort
Age-adjusted D-dimer cutoff for excluding DVT in older patients
Reasons for failure to remove IVCF
Dabigatran or warfarin for extended maintenance therapy of VTE
RVO to predict the risk of recurrent VTE
Optimal anticoagulation duration in cancer-related DVT
CTEPH prevalence after acute PE
Ruling out CTEPH after acute PE
Idrabiotaparinux for acute symptomatic PE
Download PDF